GLP-1 medications have revolutionized weight loss, helping millions shed pounds and improve their health. But what happens when the side…
Browsing: Clinical Updates
Eosinophilic Esophagitis (EoE) is emerging as a rapidly increasing immune-mediated condition affecting the esophagus. Its diagnosis requires symptoms of esophageal…
A groundbreaking study highlights the potential of artificial intelligence (AI) in enhancing colorectal adenoma (CRA) detection through fecal immunochemical tests…
With the FDA’s recent approval of Guardant Health’s Shield blood test and Exact Sciences’ Cologuard Plus stool test, colorectal cancer…
The FDA has approved a generic version of liraglutide (Victoza) for type 2 diabetes in patients aged 10 and older,…
A recent study has introduced an integrative risk score that effectively predicts the future onset of Crohn’s disease. This tool…
Pfizer has received FDA accelerated approval for BRAFTOVI (encorafenib) combined with cetuximab and mFOLFOX6 to treat metastatic colorectal cancer (mCRC)…
A new study published in Nature introduces NK2R agonists as a promising alternative to GLP-1 drugs for obesity and diabetes,…
The FDA has approved a generic version of liraglutide (Victoza) for managing blood sugar in type 2 diabetes patients aged…
The FDA has granted accelerated approval to a combination therapy led by encorafenib (Braftovi) for patients with BRAF V600E-mutant metastatic…